Valerion, Catalent deal

Catalent's Catalent Pharma Solutions Inc. subsidiary and Valerion partnered to develop Valerion's two lead preclinical candidates, VAL-1205 and VAL-1221. VAL-1205 is the delivery antibody 3E10 whic...